Biodexa Pharmaceuticals PLC ADR美股招股说明书(2025-07-18版)

shareholders identified in the Prospectus of up to an aggregate of 4,349,102,800 of our ordinary shares, nominal value £0.000001 pershare, represented by 434,901 American Depositary Shares (the “Depositary Shares”). This Prospectus Supplement is being filed in order to incorporate into and include in the Prospectus the information contained in our attached Form 6-K, filed with the Securities and Exchange Commission on July 15, 2025.This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by reference to the Prospectusexcept to the extent that the information in this Prospectus Supplement supersedes the information contained therein. Investing in our securities involves risks. See “Risk Factors” beginning on page 9 of the Prospectus and in the Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of ______________________________ The date of this Prospectus Supplement is July 18, 2025. REPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR 15d-16 OF THESECURITIES EXCHANGE ACT OF 1934 For the month of July 2025Commission File Number 001-37652Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-FxForm 40-F¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):¨Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):¨